Overview

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.

Phase:

Phase 3

Details

Lead Sponsor:

Cidara Therapeutics Inc.

Treatments:

Fluconazole
Posaconazole
Rezafungin
Sulfamethoxazole
Trimethoprim
Trimethoprim, Sulfamethoxazole Drug Combination